Kim A Papp Selected Research

efalizumab (Raptiva)

1/2008	Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial.
3/2007	Efalizumab for the treatment of psoriatic arthritis.
10/2006	Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.
9/2006	Evaluation of efalizumab using safe psoriasis control.
6/2006	The long-term efficacy and safety of new biological therapies for psoriasis.
5/2006	Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
4/2006	Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
4/2006	Long-term management of plaque psoriasis with continuous efalizumab therapy.
1/2006	A favourable benefit/risk ratio with efalizumab: a review of the clinical evidence.
1/2006	Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kim A Papp Research Topics

Disease

101	Psoriasis (Pustulosis Palmaris et Plantaris) 07/2022 - 12/2002
17	Infections 05/2022 - 12/2005
11	Neoplasms (Cancer) 05/2022 - 12/2005
11	Psoriatic Arthritis 01/2022 - 10/2004
10	Atopic Dermatitis (Atopic Eczema) 01/2022 - 02/2005
7	Pruritus (Itching) 12/2021 - 12/2003
5	Respiratory Tract Infections (Respiratory Tract Infection) 12/2021 - 03/2012
5	Inflammation (Inflammations) 01/2020 - 01/2006
4	Pain (Aches) 01/2022 - 05/2013
4	Nasopharyngitis 12/2021 - 03/2012
3	Eczema 11/2018 - 10/2017
3	Body Weight (Weight, Body) 01/2017 - 10/2010
3	Skin Neoplasms (Skin Cancer) 09/2015 - 02/2012
2	Hidradenitis Suppurativa 07/2022 - 08/2016
2	Headache (Headaches) 12/2021 - 01/2021
2	Axial Spondyloarthritis 11/2021 - 12/2020
2	Herpes Zoster 06/2021 - 11/2017
2	Candidiasis (Moniliasis) 01/2021 - 03/2017
2	Injection Site Reaction 12/2020 - 10/2017
2	Erythema 01/2020 - 03/2012
2	Communicable Diseases (Infectious Diseases) 12/2019 - 01/2019
2	Measles 01/2019 - 02/2005
2	Rubella (German Measles) 01/2019 - 02/2005
2	Neutropenia 07/2016 - 03/2012
2	Lymphoma (Lymphomas) 05/2012 - 06/2007
2	Latent Tuberculosis 07/2011 - 06/2007
1	Fatigue 01/2022
1	Chronic Disease (Chronic Diseases) 01/2022
1	Contact Dermatitis (Eczema, Contact) 12/2021
1	Folliculitis (Sycosis) 12/2021
1	Acne Vulgaris 01/2021
1	Diarrhea 01/2021
1	Oral Candidiasis (Thrush) 01/2021
1	Crohn Disease (Crohn's Disease) 01/2021
1	Hypertension (High Blood Pressure) 01/2021
1	Chickenpox 01/2019
1	Mumps 01/2019
1	Viremia 01/2019
1	Arthritis (Polyarthritis) 12/2018

Drug/Important Bio-Agent (IBA)

17	efalizumab (Raptiva)FDA Link 01/2008 - 12/2003
16	Etanercept (Enbrel)FDA Link 05/2018 - 10/2004
14	Ustekinumab (CNTO 1275)FDA Link 04/2021 - 05/2008
14	Monoclonal AntibodiesIBA 11/2020 - 03/2007
13	Adalimumab (Humira)FDA Link 07/2022 - 01/2011
11	ixekizumabIBA 01/2022 - 01/2016
10	Immunoglobulin A (IgA)IBA 03/2022 - 10/2017
10	Biological ProductsIBA 01/2022 - 10/2004
8	Janus Kinase InhibitorsIBA 06/2021 - 03/2014
7	Prostaglandins AIBA 12/2021 - 02/2012
7	brodalumabIBA 07/2021 - 03/2012
7	tofacitinibIBA 12/2018 - 03/2014
7	Immunoglobulin G (IgG)IBA 01/2018 - 11/2004
6	VaccinesIBA 05/2022 - 11/2013
6	guselkumabIBA 03/2022 - 03/2017
6	risankizumabIBA 01/2022 - 01/2017
6	Interleukin-23 (Interleukin 23)IBA 01/2020 - 05/2012
6	InterleukinsIBA 08/2018 - 05/2008
5	Infliximab (Remicade)FDA Link 01/2021 - 01/2006
5	CytokinesIBA 01/2020 - 05/2008
5	Interleukin-12 (IL 12)IBA 01/2017 - 05/2008
4	apremilastIBA 07/2022 - 05/2013
4	upadacitinibIBA 01/2022 - 01/2020
4	bimekizumabIBA 01/2021 - 08/2018
4	secukinumabIBA 01/2021 - 07/2015
4	Interleukin-17 (Interleukin 17)IBA 11/2020 - 07/2015
3	TYK2 Kinase (Tyrosine Kinase 2)IBA 07/2022 - 01/2021
3	Pharmaceutical PreparationsIBA 05/2022 - 05/2010
3	dupilumabIBA 10/2021 - 10/2017
3	betamethasone-17,21-dipropionate (betamethasone dipropionate)FDA LinkGeneric 10/2021 - 01/2003
3	calcipotriene (calcipotriol)FDA LinkGeneric 10/2021 - 01/2003
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2016 - 06/2007
3	Alefacept (Amevive)FDA Link 05/2012 - 12/2002
3	Methotrexate (Mexate)FDA LinkGeneric 10/2011 - 03/2007
3	pimecrolimus (Elidel)FDA Link 01/2006 - 02/2005
2	deucravacitinibIBA 07/2022 - 02/2022
2	Tumor Necrosis Factor InhibitorsIBA 01/2021 - 07/2011
2	RoflumilastIBA 08/2020 - 01/2020
2	Phosphodiesterase 4 InhibitorsIBA 01/2020 - 05/2013
2	AntigensIBA 10/2017 - 06/2007
2	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2017 - 07/2012
2	Ointments (Pastes)IBA 10/2016 - 07/2012
2	AntibodiesIBA 07/2015 - 02/2005
2	Calcineurin InhibitorsIBA 07/2012 - 01/2006
2	briakinumabIBA 02/2012 - 10/2011
1	Antirheumatic Agents (DMARD)IBA 01/2022
1	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 12/2021
1	tapinarofIBA 12/2021
1	Janus KinasesIBA 01/2021
1	sonelokimabIBA 01/2021
1	Creatine Kinase (Creatine Phosphokinase)IBA 01/2021
1	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 08/2020
1	Janus Kinase 1IBA 01/2020
1	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2020
1	Immunosuppressive Agents (Immunosuppressants)IBA 12/2019
1	Immunomodulating AgentsIBA 01/2019
1	Attenuated VaccinesIBA 01/2019
1	ametantrone (HAQ)IBA 12/2018

Therapy/Procedure

29	Therapeutics 05/2022 - 12/2003
10	Biological Therapy 04/2021 - 01/2006
6	Phototherapy (Light Therapy) 01/2022 - 01/2006